Nammi Therapeutics
Nammi Therapeutics is an immuno-oncology company developing platforms and products that selectively activate anti-tumor immunity within the tumor microenvironment while minimizing systemic activation. They are focused on improving safety and combining multiple immune modulators through their Masked Immunocytokine (MIC) and nanoparticle platforms. This approach aims to enhance the efficacy of cancer treatments.
Funding Round: Series B
Funding Amount: $30M
Date: 06-Aug-2024
Investors: Myeloma Investment Fund (MIF)
Markets: Immuno-oncology, Biotechnology, Drug Discovery, Life Sciences, Oncology
HQ: Los Angeles, California, United States
Founded: 2018
Website: https://www.nammirx.com/
LinkedIn: https://www.linkedin.com/company/nammi-therapeutics-inc
Leave a Comment
Comments
No comments yet.